by Kueiyu Joshua Lin, Daniel E. Singer, Robert J

Slides:

Advertisements

Similar presentations

ROCKET-AF Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial.

Advertisements

Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]

Apixaban versus Aspirin in Atrial Fibrillation Patients ≥ 75 years old: An Analysis from the AVERROES Trial Kuan H Ng, Olga O Shestakovska, John W. Eikelboom,

Efficacy and Safety of Dabigatran vs. Warfarin in Patients with Atrial Fibrillation - Japanese population in the RE-LY ® - Shinya Goto, MD., PhD. Tokai.

Warfarin Dabigatran Rivaroxaban Apixaban Edoxaban Target

The ACTIVE Investigators. N Engl J Med 2009 Apr 3 [Epub]

Rhythm and Rate Control for Atrial Fibrillation Tom Wallace, MD Cardiac Electrophysiology CHI St. Vincent Heart Clinic Arkansas.

Bleeding After Initiation of Multiple Antithrombotic Drugs, Including Triple Therapy, in Atrial Fibrillation Patients Following Myocardial Infarction and.

Gli anticoagulanti diretti nel mondo reale

Comparison of Patient Satisfaction and Time Spent in Therapeutic Range in Two Different Clinic Models Ashley Pokallus, PharmD PGY1 Pharmacy Resident—Ambulatory.

R4 문정락 / IC prof. 김진배 Lancet Haematol 2015;2: e150–59.

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation Manesh R. Patel, M.D., Kenneth W. Mahaffey, M.D., Jyotsna Garg, M.S., Guohua Pan, Ph.D.,

Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Transition of Patients From Blinded Study Drug to.

Manesh R. Patel, M.D., Kenneth W. Mahaffey, M.D., Jyotsna Garg, M.S., Guohua Pan, Ph.D., Daniel E. Singer, M.D., Werner Hacke, M.D., Ph.D., Gunter Breithardt,

Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: Evidence That D-Dimer Levels Predict Subsequent.

Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart DiseaseClinical Perspective by Michael D. Ezekowitz, Rangadham.

Nguyen Ngoc Tu1,2, Marie-Christine Morel-Kopp3, Chris Ward 3, Robert G

Case 66 year old male with PMH of HTN, DM, ESRD on renal replacement TIW, stroke in 2011 with right side residual weakness, atrial fibrillation, currently.

Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated with Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation.

Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Non-valvular Atrial Fibrillation.

Volume 149, Issue 6, Pages (June 2016)

2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation Chern-En Chiang, Tsu-Juey.

Exploring Factors Associated with Preferential Prescribing of Apixaban Over Warfarin in Patients with Non-Valvular Atrial Fibrillation Scott McColgana,

An approach to using risk scores for stroke and bleeding in clinical practice. An approach to using risk scores for stroke and bleeding in clinical practice.

Figure 1 Flow chart diagram of high-risk group AF patients

Obesity Trends* Among U.S. Adults BRFSS, 1985

Efficacy and Safety of Dabigatran vs

No evidence that AF type significantly impacts stroke risk

Copyright © 2016 American Medical Association. All rights reserved.

Safety and Effectiveness of Direct Oral Anticoagulants Versus Vitamin K Antagonists: Pilot Implementation of a Near‐Real‐Time Monitoring Program in Italy.

Health Literacy and Awareness of Atrial Fibrillation

Prediction of Atrial Fibrillation in a Racially Diverse Cohort: The Multi‐Ethnic Study of Atherosclerosis (MESA)‏ by Alvaro Alonso, Nicholas S. Roetker,

Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results From the ROCKET AF Trial by Daniel E. Singer, Anne.

Risk Factors for Rehospitalization for Acute Coronary Syndromes and Unplanned Revascularization Following Acute Myocardial Infarction by Suzanne V. Arnold,

Current and future paradigm for prognostication and testing of therapeutics in patients with heart failure using machine learning. Current and future paradigm.

RE-CIRCUIT Trial design: Patients with atrial fibrillation undergoing catheter ablation were randomized to uninterrupted dabigatran 150 mg twice daily.

Timothy A. Brighton, M. B. , B. S. , John W. Eikelboom, M. B. , B. S

Overall burden of AF associated with higher risk of thromboembolism and ischemic stroke An analysis of the KP-RHYTHM study, in patients with paroxysmal.

Nat. Rev. Cardiol. doi: /nrcardio

A Systematic Review On Different Prothrombin Complex Concentrate Strategies To Reverse Vitamin K Antagonist Therapy by Nakisa Khorsand, Hilde A.M. Kooistra,

Selecting NOACs for High-Risk Patients

Revealing Characteristics of Patients at High Risk for Developing Atrial Fibrillation.

Assessing the Risk for Stroke in Patients With Atrial Fibrillation

SAMe-TT2R2 Score, Time in Therapeutic Range, and Outcomes in Anticoagulated Patients with Atrial Fibrillation Pilar Gallego, MD, PhD, Vanessa Roldán,

Forest plot of the HRs for DOACs vs warfarin for (A) new or recurrent VTE and (B) major bleeding based on the published subanalyses of the patients with.

Alexander M. Walker, MD, DrPH, Dimitri Bennett, MD, MPH Heart Rhythm

Volume 13, Issue 1, Pages (January 2016)

Alexander M. Walker, MD, DrPH, Dimitri Bennett, MD, MPH Heart Rhythm

Influence of Renal Function on the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Non–Vitamin K Antagonist Oral Anticoagulants Matthew R.

Identifying High-Risk AF Patients

Volume 145, Issue 1, Pages (January 2014)

Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin Keitaro Senoo, MD, Marco Proietti,

Non-vitamin k antagonist oral anticoagulants in a European primary care physician survey by Claudio Cimminiello, Robert Hatala, Sami Pakarinen, Hernan.

Non-vitamin k antagonist oral anticoagulants in a European primary care physician survey by Claudio Cimminiello, Robert Hatala, Sami Pakarinen, Hernan.

NOAC Studies in VTE AF Studies Superior Outcomes.

Treatment and secondary prevention strategy diagram for VTE in patients with active cancer based on the treatment guidelines for cancer-associated VTE.

Incidence of (A) recurrent VTE and (B) major bleeding in select randomised clinical trials of LMWH for the treatment and secondary prevention of VTE in.

Receiver operating characteristic curves for the association of primary outcome using each clinical risk score and each clinical risk score adjusted for.

The American Journal of Medicine

Overall burden of AF associated with higher risk of thromboembolism and ischemic stroke An analysis of the KP-RHYTHM study, in patients with paroxysmal.

Forest plot illustrating the risk ratio of any bleeding and GRADE assessment. AF, atrial fibrillation; DOAC, advent of direct oral anticoagulants; PCI,

Although non-stroke outcomes are more common, stroke risk scores can be used for prediction in patients with atrial fibrillation Finlay A. McAlister,

Figure 1. Decision-making process of stroke prevention in patients with AF from Asia. The decision-making process includes stroke risk evaluation, OAC.

Gianluigi Savarese et al. JCHF 2016;4:

Forest plot illustrating the risk ratio of major bleeding

by John Robson, Kate Homer, Zaheer Ahmed, and Sotiris Antoniou

Forest plot illustrating the risk ratio of myocardial infarction

Forest plot illustrating risk ratio of stent thrombosis

The CHA(2)DS2-(VASc) stroke risk and HAS-BLED bleeding risk index are calculated by totalling the scores for each risk factor present.68–71 The lower graph.

Presentation transcript:

Prediction Score for Anticoagulation Control Quality Among Older Adults by Kueiyu Joshua Lin, Daniel E. Singer, Robert J. Glynn, Suzanne Blackley, Li Zhou, Jun Liu, Gina Dube, Lynn B. Oertel, and Sebastian Schneeweiss J Am Heart Assoc Volume 6(10):e006814 October 5, 2017 © 2017 Kueiyu Joshua Lin et al.

Systematic review on significant predictors for anticoagulation quality (TTR). Systematic review on significant predictors for anticoagulation quality (TTR). AF indicates atrial fibrillation; INR, international normalized ratio; TTR, time in therapeutic range; VKA, vitamin K antagonist; VTE, venous thromboembolism. Kueiyu Joshua Lin et al. J Am Heart Assoc 2017;6:e006814 © 2017 Kueiyu Joshua Lin et al.

Comparison of AUC: new geriatric score superior to SAMe‐TT2R2. Comparison of AUC: new geriatric score superior to SAMe‐TT2R2. A, Predicting TTR >70%. B, Predicting clinical outcomes. *Composite outcomes of incident stroke, systemic embolism, VTE, and major bleeding events. AF indicates atrial fibrillation; AUC, area under the receiver operating characteristic curve; INR, international normalized ratio; TTR, time in therapeutic range; VTE, venous thromboembolism. Kueiyu Joshua Lin et al. J Am Heart Assoc 2017;6:e006814 © 2017 Kueiyu Joshua Lin et al.